Getting the Ball Rolling

• What is the single most important milestone or date we are racing toward (binding offer, signing, closing, or exclusivity expiry)? Options: Binding offer, Signing (SPA execution), Closing, Exclusivity expiry, Other
• How long is your exclusivity window today, and how flexible is that window if diligence uncovers unexpected issues? Options: < 1 week, 1–2 weeks, 2–4 weeks, > 4 weeks, Unknown / flexible
• What’s your role in this transaction and who on your side will be our day-to-day contact for legal diligence? Options: PE deal partner / similar, Chief Legal Officer / GC, In-house counsel (associate), Transaction / M&A lead (non-legal), Other
• Please state the target’s industry and an approximate enterprise value band (or range) so we can prioritize regulatory and IP focus appropriately. Options: Technology / Software, Life Sciences / Biotech, Healthcare / Provider, Consumer / Retail, Manufacturing / Industrials, Financial Services, Energy / Utilities, Other
• What documents or early access can you provide immediately (data room link, management presentation, preliminary contracts list)?

What Are We Racing Against?

• If this deal slipped one week, what is the first thing that would break for you or your model? Options: Financing commitment at risk, Exclusivity lost, Regulatory timing window missed, Contractual termination risk, Other
• How much runway do the financial and commercial teams require to incorporate legal findings into valuation (same-day, 24–48 hours, one week)? Options: Same-day, 24–48 hours, Up to one week, Longer than one week, Unsure
• Are there known external deadlines—financing covenants, board votes, investor windows, regulatory filing cut-offs—that make this timeline immovable? Tell us which ones and why.
• Have you had prior deals in this industry where a legal issue extended the timeline unexpectedly? If yes, what happened and how long did the delay last? Options: Yes — short delay (days), Yes — moderate delay (weeks), Yes — major delay (months), No, Not sure / prefer to describe
• Which outcome would you prefer if we encounter a high‑impact but remediable risk late in diligence: (a) immediate price adjustment, (b) escrow/holdback, (c) unconditional walk‑away, or (d) structured remediation post‑close? Options: Immediate price adjustment, Escrow/holdback, Walk-away, Post-close remediation, Depends on severity

Who's in the Room and Who's Silent?

• Who can single-handedly approve a change to scope, fee, or timeline on your side—and who can veto the deal?
• Which internal and external advisors need to be looped into daily triage calls (financial DD, tax, tech, regulatory counsel, bankers)? Options: Financial advisors / accountants, Tax advisors, Tech / FTO specialists, Regulatory counsel, Bankers / ECM, Other
• How responsive is the seller expected to be on documentation and questions? Are there known gatekeepers or slow respondents we should plan around? Options: Very responsive, Generally responsive, Slow but cooperative, Unresponsive / guarded, Unknown
• Who at the seller side controls data room access and vendor/contractor records (CEO, GC, Head of Ops, external advisor)? Options: CEO / Founder, General Counsel, Head of Operations, External advisor / banker, Data room admin, Other
• How do you prefer we escalate critical findings—immediate hot call, end‑of‑day summary, or only at milestone reviews? Options: Immediate hot call, Same‑day summary, Daily end‑of‑day report, Only milestone reviews, Other
• Are there cultural or political dynamics (cofounder conflicts, investor sensitivities, government relationships) we should know about that change how blunt or diplomatic we must be?

What Keeps You Up at Night?

• If you had to name the single legal risk that would change your bid or make you walk away today, what is it? Options: IP ownership gaps, Contract termination on change‑of‑control, Undisclosed litigation / judgments, Regulatory or licensing failure, Antitrust/foreign investment issues, Other
• How material would that risk need to be to alter price or terms—specific dollar threshold, percentage of EV, or qualitative blocker? Options: Specific dollar amount (enter below), Percentage of EV (enter below), Qualitative blocker (must be cleared), Not sure
• Tell us about any IP‑development history we should flag (heavy contractor work, university collaborations, inherited codebases). How confident are you in the target’s assignment chain? Options: High confidence, Moderate confidence, Low confidence, Unknown / needs review
• Have you encountered change‑of‑control termination clauses in key customer or vendor contracts in this sector before? If yes, how often did they trigger material loss? Options: Never, Rarely, Occasionally, Frequently, Not sure
• Beyond facts, how would discovering a late material legal issue make you feel about the deal—blindsided, frustrated with process, defensive in negotiation, or relieved it was caught? Options: Blindsided, Frustrated, Defensive, Relieved, Other
• For litigation/regulatory matters: do you prefer our report to quantify a probable range of exposure, present scenarios, or prioritize blocking items only? Options: Quantified range of exposure, Scenario‑based (best/worst/most likely), Prioritized blocking items only, Combination

Where Could This Break the Deal?

• Which of these outcomes is your principal fear if a severe legal issue appears late: closing delay, material price haircut, indemnity shortfall, or reputational fallout? Options: Closing delay, Price haircut, Indemnity shortfall, Reputational fallout, Other
• What indemnity, cap, or escrow structures have you used successfully in the past to bridge third‑party legal exposure? Options: Standard cap (x% of EV), Escrow for specific risks, Seller reps & warranties insurance, Capped indemnity with time limits, Other
• How do you trade off speed vs. exhaustiveness in diligence—is a prioritized list of blockers enough to proceed, or do you require full workstream sign‑off before offering? Options: Blockers only (fast), Partial deep dive on high‑risk areas, Full sign‑off across workstreams, Depends on risk found
• Have you set a maximum acceptable remediation budget or valuation haircut in advance? If yes, please describe how you measure it (dollars, % EV, deal economics).
• Would you consider using third‑party instruments (RWI, escrow, structured holdbacks) to bridge gaps, or is seller willingness the gating factor? Options: Open to RWI, Prefer escrow/holdback, Seller willingness is gating, Depends on risk type, Unsure
• When a risk is flagged as a 'closing blocker' for you, what immediate next steps do you expect from legal counsel? Options: Draft PA protective language, Recommend price adjustment, Negotiate escrow/holdback, Request additional reps/warranties, Pause deal to investigate

How Should Findings Map to Value?

• If legal findings were translated perfectly into the financial model, what form would you need them in—line‑item dollar adjustments, probability‑weighted scenarios, or narrative recommendations tied to PA clauses? Options: Line‑item dollar adjustments, Probability‑weighted scenarios, Narrative recommendations + PA language, Combination
• How granular should our prioritized risk matrix be—high/medium/low, numeric probabilities, or by likely impact on closing vs. valuation? Options: High/Medium/Low, Numeric probabilities, Impact on closing vs valuation, Custom format (describe)
• Who on the buyer team must sign off on the final legal findings before they feed into price/terms (deal partner, CFO, investment committee, GC)? Options: Deal partner, CFO/Finance, Investment committee, General Counsel, Other
• When we deliver draft PA language, do you prefer: short bullets to negotiate, near‑final clauses for redlining, or both staged by severity? Options: Short bullets, Near‑final clauses, Both staged, Depends on issue
• How would you like us to surface items for the financial advisors—daily triage highlights, a single integration memo, or direct coordination calls? Options: Daily triage highlights, Single integration memo, Direct coordination calls, Combination
• Are there internal naming or categorization conventions (e.g., 'closing blocker', 'price adjust', 'post‑close remediation') we should adopt to make handoffs frictionless? Options: Use your standard labeling (we'll adopt), Use our standard labeling, Agree on shared taxonomy, No preference

How Do You Want Us to Run This?

• If you could design the ideal diligence rhythm for a 2–3 week window, what would it be—daily half‑hour triage, end‑of‑day summaries, or twice‑daily checkpoints? Options: Daily 30‑minute triage, End‑of‑day summaries, Twice‑daily checkpoints, Weekly milestone reviews, Other
• What deliverable cadence feels most useful to you: an early red‑flag memo within 48 hours, a mid‑point prioritized findings list, and a final risk matrix at close? Options: 48‑hour red flag + final, Mid‑point list + final, Multiple rapid updates (daily), Custom cadence (describe)
• What level of staffing visibility do you need—names and bios of assigned lawyers, partner oversight only, or skillset summary (IP, employment, litigation) sufficient? Options: Names + bios, Partner oversight only, Skillset summary, Other
• How strict must confidentiality and access rules be for our team (e.g., Chinese‑walling, limited copies, no external consultants), and are there specific NDAs or vendor agreements to sign? Options: Very strict (detailed controls), Standard professional confidentiality, Require NDAs, Unknown / provide details
• If we discover privileged or highly sensitive materials, how do you want us to handle them—flag and quarantine, skip review unless approved, or escalate for immediate guidance? Options: Flag and quarantine, Skip unless approved, Immediate escalation, Other
• Are there internal SLA expectations for turnaround on questions from financial modelers or negotiators (e.g., 4 hours, 24 hours)? Options: 4 hours, 24 hours, 48 hours, Flexible / as needed

Next Steps & Mutual Signals

• What would make you feel confident to sign an engagement today—clear scope, capped fee, time‑boxed SLAs, or a pilot tranche? Options: Clear scope, Capped fee, Time‑boxed SLAs, Pilot tranche, Other
• Who on your approval chain needs an engagement memo or SOW, and what timeline do they require to approve before we start?
• Are there procurement, compliance, or spend‑authorization steps we should expect before counsel can be engaged (PO, vendor form, AML checks)? Options: Purchase Order (PO), Vendor form, AML/KYC checks, No procurement required, Other
• What constraints should we be aware of for kicking off immediately (budget ceilings, calendar blackouts, seller availability)?
• If we deliver a concise prioritized findings memo within your timeline, what will success look like to you 72 hours after delivery? Options: Price adjustment agreed, Escrow/holdback agreed, Negotiations proceed without delay, Decision to walk away, Other

• Current State & Deal Constraints Alignment
• Workstream Facts Walkthrough — IP & Material Contracts
• Workstream Facts Walkthrough — Employment, Litigation & Regulatory
• Triage Findings & Deal-Outcome Mapping (Diagnosis → Proof → Validation)
• Validation, Finalization & Next Steps

• Define the short list of items to escalate to deal committee and schedule the findings presentation.
• Legal team to populate the issue log with IP and contract facts, evidence links, and preliminary severity tags.
• Request and track missing assignments, license schedules, and counterpart contact lists from seller.
• Assign a contract owner to lead novation/assignment remediation planning for high-risk contracts.
• Recap & Objective
• Document employment, litigation, and regulatory facts with preliminary impact estimates.
• Identify which items must be treated as potential closing blockers and require urgent mitigation.
• Create a short list of high-priority items to drive the Triage -> Deal Outcome session.
• Legal team to calculate approximate exposure ranges for the top 3 litigation/regulatory items.
• HR lead to produce a short memo on change-of-control liabilities and estimated cash impact.
• Regulatory lead to confirm likelihood and timeline for any required filings (Hart-Scott-Rodino, FDI, sectoral approvals).
• Methodology & Rules of Engagement
• Agree which findings are closing blockers, which are price items, and which are operational/post-close remediation.
• Obtain buyer validation on recommended PA language and high-level financial exposure estimates.
• Introductions & Objectives
• Legal team to draft the findings report sections and proposed PA clauses for validated high-impact items.
• Financial advisor to produce a one-page sensitivity showing purchase-price impact ranges for agreed items.
• Schedule deal-committee presentation and assign presenters for each escalated issue.
• Agree on the final deliverable format, SLAs, and the immediate execution plan to enter Mutual Commit.
• One-sentence Recap & Acceptance Check
• Buyer explicitly validates that the Solution Experience proved the future state against the current facts.
• Assign owners and deadlines for the next-phase deliverables and remediation actions.
• Finalize and circulate the draft findings report and prioritized risk matrix within 24 hours.
• Legal team to produce signed-off PA language snippets for each validated high-impact finding.
• Confirm staffing roster and on-call schedule for the exclusivity window and daily triage cadence.
• Produce and document a crystal-clear single-sentence current state.
• Agree the quantified consequence (time/$/regulatory impact) for the deal team.
• Define a one-sentence future state to prove against during the Solution Experience.
• Clear list of immediate data access items with owners and deadlines.
• Buyer to circulate the single-sentence current state and top 5 risk priorities in writing.
• Seller to confirm data-room access and upload any missing high-priority docs within 24 hours.
• Assign workstream leads and schedule the Workstream Facts Walkthrough sessions.
• Recap of Current/Future State
• Surface and document IP and contract facts with the underlying evidence called out.
• For each fact, attach an explicit consequence and preliminary severity (blocker/price/item).
• Identify and assign owners for immediate document-gap remediation to enable definitive triage.
• Review Pre-work: Single-sentence Current State
• Employment & Benefits Facts
• IP Ownership Chain Facts
• Walkthrough of Draft Findings & Risk Matrix
• Top Findings Presentation (Diagnosis)
• Proof: Remediation Options & Timeline
• Agree SLAs, Deliverable Format & Signoffs
• Employment Consequence Mapping
• IP Consequence Assessment
• Quantify Consequence
• Confirm Resourcing & Rapid-Turn Plan
• Define Future State (one sentence)
• Litigation & Claims Facts
• Material Customer & Supplier Contracts Facts
• Deal Mapping: Recommended PA Language & Financial Impact
• Validation & Decision Calls
• Contracts Consequence Assessment
• Immediate Next Steps & Owner Commitments
• Regulatory & Investigations Facts
• Timeline & Decision Criteria
• Evidence Gaps & Document Requests
• Flag High-Risk Items for Triage
• Escalation & Presentation Plan
• Immediate Data / Access Gaps

• Verify corporate authority and ownership records
• IP chain-of-title review and extraction
• Freedom-to-operate patent landscape memo
• Map change-of-control and assignment clauses
• Review employment agreements for non-compete/retention
• Quantify litigation exposure and indemnity gaps
• Identify regulatory obligations and consent decrees
• Analyze antitrust and foreign-investment filing needs
• Review data privacy and cross-border transfer risks
• Review environmental permits and contamination liabilities
• Draft purchase-agreement protective language and carveouts
• Deliver prioritized risk-rated findings report

Verify corporate authority and ownership records

• Is the target organized as a single legal entity or multiple related entities? Options: Single entity, Multiple related entities, Complex structure with SPVs or joint ventures
• List the jurisdiction(s) of incorporation and principal places of business for the target and material subsidiaries
• Do you need a full cap table and stock ledger review (including option/warrant pools and convertible instruments)? Options: Yes, No, Partial (only material holders)
• Have there been any material ownership transfers, buybacks, or shareholder agreements in the last 24 months? Options: Yes, No, Unknown
• Should we confirm authority for the proposed form of transaction (share sale v. asset sale) and any required corporate approvals? Options: Yes, confirm authority for share sale, Yes, confirm authority for asset sale, Confirm both, No
• Are any equity holders subject to transfer restrictions, pre-emptive rights, or foreign ownership limits that could impede closing? Options: Yes, No, Unknown

IP chain-of-title review and extraction

• Which IP types are material (select all that apply)? Options: Patents, Trademarks/brands, Copyrights, Trade secrets, Domain names, Software/Source code
• Do you require extraction of patent and trademark registration data (numbers, filing dates, owners, status)? Options: Yes, No
• Are key engineers, inventors, or authors contractors or third-party vendors whose assignment status is uncertain? Options: Yes, No, Unknown
• Provide any known IP-related agreements to prioritize (e.g., contributor agreements, license-in, development agreements)
• Do you want us to extract and flag missing or ambiguous chain-of-title documents (e.g., assignments, employment invention assignments)? Options: Yes, No
• Should we include a recommended remediation checklist for gaped assignments and recordation steps? Options: Yes, No

Freedom-to-operate patent landscape memo

• Is a freedom-to-operate (FTO) assessment needed for specific products or the entire product line? Options: Specific products (please list), Entire product line, Not required
• Provide target products, SKUs, or technology areas to scope the patent search
• What jurisdictions are critical for FTO (select all that apply)? Options: United States, EU (specify member states), China, Japan, Other (specify)
• Do you require patent claim analysis and potential design-around recommendations? Options: Yes, No
• What level of deliverable detail do you prefer for the memo? Options: Executive summary + risk buckets, Detailed claim charts and citations, Both
• Is speed prioritized (rapid high-level memo) or comprehensiveness (deeper search and analysis)? Options: Rapid/high-level (short turnaround), Comprehensive (longer turnaround)

Map change-of-control and assignment clauses

• Which agreement types should we prioritize for COC and assignment mapping (select all that apply)? Options: Customer contracts, Supplier/vendor agreements, Licenses (inbound/outbound), Real estate/leases, Loan/credit agreements, Technology/development agreements
• Do you need automatic extraction of change-of-control, assignment, and consent provisions from the data room? Options: Yes, No
• Are there known counterparties likely to enforce COC clauses (e.g., strategic customers or licensors)? Options: Yes, No, Unknown
• Should we produce a mapped register indicating which contracts require consent or will terminate on change of control? Options: Yes, No
• Do you want proposed PA language or negotiation talking points to address termination/consent risks? Options: Yes, propose PA language, Yes, provide negotiation points only, No
• How important is quantifying commercial impact (e.g., lost revenue) from COC-triggered terminations? Options: Critical, Useful but not critical, Not required

Review employment agreements for non-compete/retention

• Do you want review of employment agreements, offer letters, contractor agreements, and equity grant terms? Options: All of the above, Employment agreements only, Employment + contractors, Other (specify)
• Are there identified key employees or groups whose retention is critical post-close? Options: Named key employees (please list), Functions/teams (e.g., R&D, sales), No specific key employees
• Should we flag change-in-control severance, automatic vesting, or clawback provisions? Options: Yes, No
• Do you require jurisdictional analysis for enforceability of non-competes and restrictive covenants? Options: Yes, specify jurisdictions, No
• Do you want recommended retention/offer structures or PA protections related to employee liabilities? Options: Yes, No
• Are there unionized workforces, collective bargaining agreements, or pending labor disputes? Options: Yes, No, Unknown

Quantify litigation exposure and indemnity gaps

• Provide known pending or threatened litigation, arbitration, or regulatory enforcement matters to prioritize
• Do you require probability-weighted exposure estimates and high/medium/low buckets for each matter? Options: Yes, probability-weighted, High/Medium/Low qualitative only, No
• Should we review indemnity caps, baskets, survival periods, and escrow arrangements in prior templates or target contracts? Options: Yes, No
• Do you want us to identify contingent liabilities not covered by indemnities (e.g., pension deficits, environmental liabilities)? Options: Yes, No
• Are there insurer policies (D&O, GL, E&O) you want us to collect and assess for coverage gaps? Options: Yes, No, Unknown
• Should we prepare draft PA indemnity language and suggested monetary caps tied to quantified exposures? Options: Yes, No

Identify regulatory obligations and consent decrees

• Are there industry-specific regulatory regimes that apply (select all that apply)? Options: Healthcare, Financial services, Telecom, Energy/Utilities, Transportation, Other (specify)
• Are there active regulatory investigations, enforcement actions, or consent decrees affecting the target? Options: Yes, No, Unknown
• Do you want a review of licensing, permitting, and registration requirements required for post-close operations? Options: Yes, No
• Should we identify regulatory approvals or conditions that could delay or condition closing? Options: Yes, No
• Do you require recommended compliance remediation steps and estimated timelines/costs to cure identified issues? Options: Yes, No
• Is coordination with the buyer's regulatory advisors or subject-matter counsel required during diligence? Options: Yes, No

Analyze antitrust and foreign-investment filing needs

• Provide target/combined revenue and employee thresholds relevant to Hart-Scott-Rodino or other thresholds
• Which jurisdictions are material for antitrust or foreign investment review (select all that apply)? Options: United States, EU/UK, China, Brazil, Australia, Other (specify)
• Do you anticipate significant overlap with competitors or market share concerns that could trigger a second‑request or remedy? Options: Yes, No, Unknown
• Are there national security or foreign investment sensitivities (e.g., critical infrastructure, defense, data flows)? Options: Yes, No, Unknown
• Should we prepare filing strategies, timelines, and estimate fees/clearance timelines for required jurisdictions? Options: Yes, No
• Do you want recommended deal structures (hold-separate, divestiture risks) to minimize filing burdens? Options: Yes, No

Review data privacy and cross-border transfer risks

• Does the target process personal data subject to GDPR, CCPA, or other data protection laws? Options: Yes (GDPR), Yes (CCPA), Yes (other), No, Unknown
• Are there cross-border data transfers, international cloud providers, or subprocessors to map? Options: Yes, No, Unknown
• Do you require assessment of data processing agreements, privacy notices, and security incident history? Options: Yes, No
• Should we identify required remediation (SCCs, BCRs, DPA updates) and estimate implementation timeline? Options: Yes, No
• Are there significant data subject rights requests, breaches, or outstanding regulator inquiries? Options: Yes, No, Unknown
• Do you want recommended PA representations, indemnities, and holdbacks specific to privacy risks? Options: Yes, No

Review environmental permits and contamination liabilities

• Does the target own or operate properties requiring environmental permits (air, water, waste, wastewater)? Options: Yes, No, Unknown
• Are there historical operations or sites with potential contamination or legacy cleanup obligations? Options: Yes, No, Unknown
• Do you require review of environmental insurance, compliance audits, and consent orders? Options: Yes, No
• Should we quantify potential remediation costs or identify regulatory closure/permit transfer requirements? Options: Yes, No
• Are there cross-border environmental exposures or multi-jurisdictional permitting issues? Options: Yes, No, Unknown
• Do you want draft PA protective provisions (survival, indemnity, escrow) for environmental liabilities? Options: Yes, No

• Engagement Letter / Retainer Agreement
• Statement of Work (SOW)
• Fee Schedule & Payment Terms
• Report Format & Deliverables
• Confidentiality & Data Room Access Protocol
• Service Levels & Turnaround SLAs
• Signoff & Approval Matrix
• Conflict Check & Waiver
• Third‑Party Counsel & Subcontracting Consent
• Data Preservation & Privilege Protocol
• Regulatory & Filing Responsibilities

• Findings Presentation & Risk Prioritization
• Financial & Deal Impact Sync (Bankers + Financial Advisors)
• Purchase Agreement Drafting Workshop (Redline & Clause Decisions)
• Remediation & Post‑Close Execution Roadmap
• Executive Closeout Briefing — Decision & Signoffs

• Agree on budget ranges and funding sources for remediation work and how costs influence final consideration.
• Finalize redlines for the highest‑priority clauses so the deal team can present concrete asks to the seller.
• Create a decision log that records tradeoffs and fallback positions for negotiators.
• Identify any open legal items requiring further diligence or seller confirmation post‑redline.
• Produce the redline version of the PA with tracked decisions and circulate to deal team and bankers.
• List outstanding confirmations to request from the seller (e.g., IP assignment proofs, consent timelines).
• Assign follow‑up owners for any clauses deferred for later negotiation or escalation to partners.
• Remediation Priorities Recap
• Produce a time‑boxed remediation plan with owners and milestones that reduces execution risk and supports the negotiated deal protections.
• One‑sentence Current State
• Establish verification criteria that the buyer will accept to release escrow or certify remediation completion.
• Deliver a 30/60/90 remediation plan with named owners, estimated costs, and deliverables for inclusion in the closing binder.
• Draft a checklist of pre‑close certificates and post‑close attestations tied to escrow release milestones.
• Schedule recurring post‑close remediation status calls with clear reporting templates.
• One‑sentence Current State & Ask
• Obtain explicit executive approval on the negotiation strategy, required asks, and who is authorized to sign the final agreements.
• Confirm whether to proceed to exchange/redline with the seller or to pause/escalate based on remaining risks.
• Agree on immediate public/LP‑facing messaging if material issues affect timing or valuation (if applicable).
• Prepare and distribute an executive decision memo capturing approvals, signature authorities, and next steps.
• If approved, instruct counsel to send the finalized redline package to the seller and schedule the negotiation exchange.
• If escalation required, compile a short list of options with risk/reward for partner signoff within 24 hours.
• Achieve a shared, one‑sentence articulation of the current state and the three highest closing blockers.
• Secure alignment on which risks must be addressed pre‑close versus via post‑close remediation and indemnity mechanisms.
• Obtain validation that the proposed price/indemnity recommendations are sufficient to proceed to PA negotiation or require escalation.
• Identify immediate follow‑ups and owners to feed the financial model and PA drafting workshops.
• Circulate the prioritized risk matrix and annotated slide deck with mapping to proposed financial protections.
• Produce a one‑page executive summary (current state, consequences, recommended ask) for bankers and CLOs.
• Tag each high/medium risk with suggested PA clause language and responsible internal owner for negotiation.
• Recap of Top Legal Risks (1‑sentence each)
• Convert legal risk assessments into modelable dollar impacts and agreed financial negotiation levers.
• Agree on the target escrow/holdback sizing and whether RWI or specific indemnities are needed for key risks.
• Produce an itemized list of asks for the seller to be used in the PA redline workshop.
• Provide updated financial model inputs reflecting agreed legal adjustments and circulate to deal team.
• Prepare an ask list with dollar ranges and rationales for the PA drafting session.
• Schedule a follow‑up with the bankers to finalize negotiation sequencing and escalation triggers.
• Prework Confirmation & Objectives
• Top Closing Blockers — Clause‑by‑Clause
• Top 3 Closing Blockers & Proposed Remedies
• Owners, Milestones & Timing
• Quantification Methodology
• Quantified Consequence Summary
• Indemnity, Caps, Baskets & Survival
• Prioritized Risk Matrix Walkthrough
• Net Economic & Timing Impact
• Mapping to Financial Model
• Cost Estimates & Budgeting
• Negotiation Priorities & BATNA
• Escrow/Holdback Mechanics & Claims Process
• Decision & Signoffs
• Mapped Deal Responses (Price/Indemnity/Escrow)
• Gating & Verification Criteria for Closing
• Integration Handoff & Reporting Cadence
• Document Decisions & Draft Final Redlines
• Draft PA Language Highlights
• Decision & Next Steps for Deal Team
• Validation & Decision Points